The Food and Drug Administration ... to the FDA, the company said it expected the agency would decide on approval by the end of March. Donanemab is part of a class of Alzheimer's treatments ...

Share on Pinterest The FDA has approved the use of the drug donanemab for early Alzheimer’s treatment. Sarah Silbiger/Getty Images A panel of independent advisors to the FDA previously endorsed ...

The Food and Drug ... Alzheimer's drug donanemab, which slowed the early stages of the fatal mind-robbing disease in studies. The approval comes less than a month after an FDA advisory committee ...

Donanemab (Kisunla), a new drug to treat Alzheimer's disease, was approved by the U.S. Food and Drug Administration on ...

setting the stage for the FDA’s sign-off. Eli Lilly’s drug — Kisunla, the brand name for donanemab — is one of the few treatments developed for Alzheimer’s that modifies the underlying ...

The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by ...

IMPORTANT NEWS TONIGHT IN THE BATTLE AGAINST ALZHEIMER’S DISEASE, THE FOOD AND DRUG ADMINISTRATION JUST APPROVED A SECOND NEW DRUG TO FIGHT THE PROGRESS OF THE DISEASE AND NEUROLOGISTS SAY THIS ...

Eli Lilly’s donanemab—to be sold under the brand name Kisunla—received regulatory approval as a monthly injection after an 18 ...

The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease. Donanemab, made by ...

According to Lilly, donanemab slowed Alzheimer’s disease progression by 35 percent relative to placebo treatment, in an 18-month clinical trial that enrolled 1,700 patients with early-stage disease.

The U.S. Food and Drug Administration (FDA) has approved a new medication for people with Alzheimer’s disease. Eli Lilly’s Kisunla (donanemab) is a once-monthly injection intended for adults ...